Indian Society10 October 20262 min read
WHO issues first child obesity guidelines, bars drugs and surgery under age 10
The World Health Organization (WHO) has released its first clinical guidelines on managing obesity in children and adolescents, with different rules by age. They advise against weight-loss drugs and bariatric surgery for children under nine and permit restricted, conditional medical interventions for adolescents aged 10 to 19.
What the guidelines allow and prohibit
For children aged 0 to 9, the guidelines strongly advise against anti-obesity drugs, including GLP-1 receptor agonists, and against bariatric surgery such as gastric bypass. Family-centred behavioural changes, structured nutrition and physical activity are the only standard of care for this group.
For adolescents aged 10 to 19, approved anti-obesity medicines may be considered only when a supervised multimodal lifestyle programme fails to achieve the desired results. Bariatric surgery may be considered under strict conditions for adolescents with severe obesity.
The guidelines also say obesity care should address anxiety, depression, low self-esteem, stigma and bullying, through family-engaged and age-appropriate care. They conditionally recommend active video games (exergames, which encourage bodily movement as part of gameplay), pedometers, accelerometers and fitness applications to replace sedentary screen time with active movement.
Why drugs are restricted
The WHO said long-term clinical trial data are absent on the paediatric safety, efficacy, treatment duration and tapering protocols of anti-obesity drugs such as semaglutide. On surgery, medical consensus cautions that paediatric bariatric surgery carries risks of micronutrient malabsorption and impaired physiological growth.
The burden globally and in India
As of 2024, 170 million children and adolescents aged 5 to 19 live with obesity worldwide: 70 million aged 5 to 9 and 100 million aged 10 to 19. The fastest rise is in low- and middle-income countries (LMICs).
In India, a Lancet study shows the number of obese boys rose from 0.2 million in 1990 to 7.3 million in 2022, and of obese girls from 0.2 million to 5.2 million. The Comprehensive National Nutrition Survey (CNNS) projects that India will have over 27 million obese young people aged 5 to 19, or 11% of the global burden. This adds to the country's dual burden of malnutrition.
The Central Drugs Standard Control Organisation (CDSCO) has approved semaglutide for adolescents aged 12 and above, strictly for morbid obesity with comorbidities such as non-alcoholic fatty liver disease (NAFLD) and prediabetes.